Abstract
The use of preimplantation genetic testing for aneuploidy (PGT-A) has been shown to improve live birth rate per embryo transfer (ET) and reduce pregnancy loss.1 Whether PGT-A is beneficial in donor oocyte recipient cycles, with lower expected rates of aneuploidy, is less clear.2-4 A major concern is the possible lower positive predictive value of PGT-A when the technology is used to screen young donor-oocyte derived embryos, which may reduce the number of healthy embryos available for transfer and/or cryopreservation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
